ALDORIL D30 Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Aldoril D30, and when can generic versions of Aldoril D30 launch?
Aldoril D30 is a drug marketed by Merck and is included in one NDA.
The generic ingredient in ALDORIL D30 is hydrochlorothiazide; methyldopa. There are thirty-two drug master file entries for this compound. Additional details are available on the hydrochlorothiazide; methyldopa profile page.
Summary for ALDORIL D30
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 95 |
Formulation / Manufacturing: | see details |
DailyMed Link: | ALDORIL D30 at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for ALDORIL D30
US Patents and Regulatory Information for ALDORIL D30
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Merck | ALDORIL D30 | hydrochlorothiazide; methyldopa | TABLET;ORAL | 013402-003 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |